Tune into Better Edge as we sit down with Emma Barber, MD, director of Robotic Surgery in the Division of Gynecologic Oncology at Northwestern Medicine. Dr. Barber is an accomplished researcher, having published more than 45 peer-reviewed articles and five book chapters.

In this episode, Dr. Barber covers the game-changing study results from the phase 3 KEYNOTE-775 trial. The combination of lenvatinib and pembrolizumab has transformed the landscape of advanced endometrial cancer treatment, showcasing remarkable improvements in progression-free survival and overall survival rates. Gain valuable insights into the potential implications of these findings and how to incorporate this innovative approach into clinical practice.